1314241-44-5 Usage
Description
UNC 669, also known as (5-Bromopyridin-3-yl)(4-(pyrrolidin-1-yl)piperidin-1-yl)methanone, is a selective inhibitor of malignant brain tumors (MBT). It is a compound with potential therapeutic applications in the treatment of brain cancer due to its ability to target and inhibit the growth of malignant brain tumor cells.
Uses
Used in Pharmaceutical Industry:
UNC 669 is used as a selective inhibitor for malignant brain tumors (MBT) for its ability to specifically target and inhibit the growth of these tumor cells. This selective action makes it a promising candidate for the development of targeted therapies against brain cancer.
Used in Oncology Research:
In the field of oncology, UNC 669 is used as a research tool to study the mechanisms underlying the growth and progression of malignant brain tumors. Its selective inhibitory properties allow researchers to investigate the molecular pathways involved in MBT development and identify potential therapeutic targets for the treatment of brain cancer.
Used in Drug Development:
UNC 669 serves as a lead compound in the development of new drugs for the treatment of malignant brain tumors. Its selective targeting of MBT cells makes it a valuable starting point for the design and synthesis of more potent and specific inhibitors that can be used in combination with other treatments to improve patient outcomes.
Used in Cancer Treatment:
As a selective inhibitor of malignant brain tumors, UNC 669 is used in cancer treatment to provide a targeted approach to managing brain cancer. Its potential to inhibit tumor growth and progression without affecting healthy cells may offer a more effective and less toxic treatment option for patients with MBT.
Used in Drug Delivery Systems:
Similar to gallotannin, UNC 669 can also benefit from novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles can be employed as carriers for UNC 669 delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes in the treatment of malignant brain tumors.
Biological Activity
unc 669 is a potent antagonist of l3mbtl1 (ic50=4.2 μm) and l3mbtl3 (ic50=3.1 μm).there is less bio-data supported for unc669. unc1679 is an analog of unc669. unc1215 is the first potent and selective antagonism of a methyl-lysine reader protein, l3mbtl3, which antagonizes the mono- and dimethyl-lysine reading function of l3mbtl3. [1]lysine methylation is a key epigenetic landmark, the dysregulation of which is related to many diseases. unc1679 maintains in vitro and cellular potency with improved selectivity against other mbt-containing proteins. the antagonists described were also found to effectively interact with unlabeled endogenous l3mbtl3 in cells. [1]
references
1. james li, korboukh vk, krichevsky l et al. small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for l3mbtl3. j med chem. 2013 sep 26;56(18):7358-71. doi: 10.1021/jm400919p. epub 2013 sep 16.
Check Digit Verification of cas no
The CAS Registry Mumber 1314241-44-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,4,2,4 and 1 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1314241-44:
(9*1)+(8*3)+(7*1)+(6*4)+(5*2)+(4*4)+(3*1)+(2*4)+(1*4)=105
105 % 10 = 5
So 1314241-44-5 is a valid CAS Registry Number.
1314241-44-5Relevant articles and documents
Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists
Simhadri, Chakravarthi,Daze, Kevin D.,Douglas, Sarah F.,Milosevich, Natalia,Monjas, Leticia,Dev, Amarjot,Brown, Tyler M.,Hirsch, Anna K. H.,Wulff, Jeremy E.,Hof, Fraser
supporting information, p. 1444 - 1456 (2019/08/02)
Chromobox homolog 7 (Cbx7) is an epigenetic modulator that is an important driver of multiple cancers. It is a methyl reader protein that operates by recognizing and binding to methylated lysine residues on specific partners. Herein we report our efforts to create low-molecular-weight inhibitors of Cbx7 by making rational structural adaptations to inhibitors of a different methyl reader protein, L3MBTL1, inhibitors that had previously been reported to be inactive against Cbx7. We evaluated each new inhibitor for Cbx7 inhibition by fluorescence polarization assay, and also confirmed the binding of selected inhibitors to Cbx7 by saturation-transfer difference NMR spectroscopy. This work identified multiple small-molecule inhibitors with modest (IC50: 257–500 μm) potency.
